eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

1/2010
vol. 35
 
Share:
Share:
more
 
 
abstract:

Review paper
Angiogenesis as a target for therapy in colorectal cancer

Barbara J. Bałan, Robert Słotwiński

Centr Eur J immunol 2010; 35 (1): 45-51
Online publish date: 2010/04/06
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Colorectal cancer is the second most common cause of death in cancer patients worldwide and difficult to treat, especially in advanced stages. Angiogenesis is a crucial process in colorectal cancer growth, development and dissemination, with significant implications for clinical management. Surgery followed by chemo- and radiotherapy is still the treatment of choice for most patients with colorectal cancer, although in advanced stages its results are frequently not satisfactory. However, inhibition of angiogenesis has been implicated as the potential, clinically effective, additional treatment strategy in advanced colorectal cancer, as antiangiogenic drugs allow controlling the tumor growth. Accordingly, the number of clinical trials confirmed, that anti-angiogenic therapy prolonged survival of colorectal cancer patients. However, the process of tumor angiogenesis and its regulation are highly complex. It depends on the balance between pro- and anti-angiogenic factors, secreted by endothelial, tumor and host-infiltrating cells. Therefore, development of efficient anti-cancer treatment targeting primarily tumor angiogenesis might be a major step in oncology.
keywords:

angiogenesis, anti-angiogenic drugs, colorectal cancer

FEATURED PRODUCTS
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe